NDANASALSPRAY, METERED
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANCENASE AQ is a metered nasal spray containing beclomethasone dipropionate monohydrate, a corticosteroid approved by the FDA in 1987. It is indicated for allergic rhinitis and nasal polyp management by reducing nasal inflammation. The drug works as a topical corticosteroid that suppresses local immune and inflammatory responses in the nasal cavity.
LOE Approaching
As an older product approaching loss of exclusivity with 30% competitive pressure, the brand team is likely focused on cost management and defending market share against generic and branded alternatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VANCENASE AQ offers limited career growth potential given its mature lifecycle and approaching loss of exclusivity. Roles are primarily defensive and cost-focused, with emphasis on brand loyalty and market share retention rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on VANCENASE AQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.